The Ormseth lab at VUMC is conducting a clinical trial in patients with rheumatoid arthritis (RA) to test a new drug, 2-HOBA.
2-HOBA is present in buckwheat and was identified at Vanderbilt as a substance that can block some of the down stream products of oxidative stress. We know that oxidative stress is increased in patients with RA. Products of oxidative stress may increase inflammation and blood pressure in patients with RA. We want to see if 2-HOBA can reduce RA disease activity and blood pressure.
We are looking for patients with RA who have at least 4 tender or swollen joints to be in this study.
If you are enrolled in the study, you will receive either 2-HOBA or an identical placebo to take three times a day for about 4 weeks. You will have two study visits where you will have an exam, complete a questionnaire, and collect blood and urine. Around the time of each study visit you will wear a blood pressure monitor for approximately 24 hours during your normal daily activities. During the course of the study, you will be asked to not change your rheumatoid arthritis medications, and participants with childbearing potential will be asked to use effective birth control throughout the study and four weeks after completion. Participants will be compensated.
A pre-screen survey for eligibility can be found here: https://redcap.vanderbilt.edu/surveys/?s=LWXEKLNWWTTJ3FKH
For more information, please contact: Annette Oeser at 615-322-3778 or annette.oeser@vumc.org